Review



combo anti mouse cd8α  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Bio X Cell combo anti mouse cd8α
    pRLN therapy remodels immune microenvironment in the metastatic lesion. a Relative mRNA expression of chemokines and cytokines in the liver of male mice bearing CT26-FL3 liver metastasis receiving PBS or pRLN therapy on day 14 (4 days after the last injection) ( n = 6). b <t>CD8</t> + T cells, CD4 + T cells, CD8 + /CD4 + ratio, activated DCs, M1/M2 ratio, Treg cells, and MDSC in the liver of male mice bearing CT26-FL3 liver metastasis receiving various treatments on day 14, analyzed by flow cytometry ( n = 3). c CD4 + or CD8 + T-cell depletion scheme for pRLN + pPD-L1 trap group and the metastatic growth curve ( n = 5). Significant differences were assessed in ( a , b ) using t test, in ( c ) using two-way ANOVA with multiple comparisons. Results are presented as mean (SD). * p < 0.05, ** p < 0.01, *** p < 0.001, n.s., not significant
    Combo Anti Mouse Cd8α, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 310 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1-mouse+cd8+ab+(clone+53-6%2E7)+antibody/InVivoMAb+anti-mouse+CD8%CE%B1/pmc06611764-285-46-51
    Average 96 stars, based on 310 article reviews
    combo anti mouse cd8α - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy"

    Article Title: Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy

    Journal: Nature Communications

    doi: 10.1038/s41467-019-10893-8

    pRLN therapy remodels immune microenvironment in the metastatic lesion. a Relative mRNA expression of chemokines and cytokines in the liver of male mice bearing CT26-FL3 liver metastasis receiving PBS or pRLN therapy on day 14 (4 days after the last injection) ( n = 6). b CD8 + T cells, CD4 + T cells, CD8 + /CD4 + ratio, activated DCs, M1/M2 ratio, Treg cells, and MDSC in the liver of male mice bearing CT26-FL3 liver metastasis receiving various treatments on day 14, analyzed by flow cytometry ( n = 3). c CD4 + or CD8 + T-cell depletion scheme for pRLN + pPD-L1 trap group and the metastatic growth curve ( n = 5). Significant differences were assessed in ( a , b ) using t test, in ( c ) using two-way ANOVA with multiple comparisons. Results are presented as mean (SD). * p < 0.05, ** p < 0.01, *** p < 0.001, n.s., not significant
    Figure Legend Snippet: pRLN therapy remodels immune microenvironment in the metastatic lesion. a Relative mRNA expression of chemokines and cytokines in the liver of male mice bearing CT26-FL3 liver metastasis receiving PBS or pRLN therapy on day 14 (4 days after the last injection) ( n = 6). b CD8 + T cells, CD4 + T cells, CD8 + /CD4 + ratio, activated DCs, M1/M2 ratio, Treg cells, and MDSC in the liver of male mice bearing CT26-FL3 liver metastasis receiving various treatments on day 14, analyzed by flow cytometry ( n = 3). c CD4 + or CD8 + T-cell depletion scheme for pRLN + pPD-L1 trap group and the metastatic growth curve ( n = 5). Significant differences were assessed in ( a , b ) using t test, in ( c ) using two-way ANOVA with multiple comparisons. Results are presented as mean (SD). * p < 0.05, ** p < 0.01, *** p < 0.001, n.s., not significant

    Techniques Used: Expressing, Injection, Flow Cytometry

    Related Articles

    Plasmid Preparation:

    Article Title: Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
    Article Snippet: .. PBS, OxP (6.0 mg kg -1 , i.p.), anti-mouse PD-L1 mAb (α-PD-L1, Bioxcell, clone 10 F.9G2, 100 μg per mouse, i.p.), LPD-GFP plasmid (pGFP, 50 μg plasmid per mouse, i.v.), LPD-PD-L1 trap plasmid (PD-L1 trap, 50 μg plasmid per mouse, i.v.), OxP + α-PD-L1, OxP + PD-L1 trap, anti-mouse CD8α (α-CD8, Bioxcell, clone 53-6.72, 200 μg per mouse, i.p.) or anti-mouse CD4 (α-CD4, Bioxcell, clone GK1.5, 200 μg per mouse, i.p.) were given at respective schedules. ..

    Article Title: Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy
    Article Snippet: .. PBS, pGFP LCP (30 μg pDNA per mouse, i.v.), pRLN LCP (30 μg pDNA per mouse, i.v.), pPD-L1 trap LCP (30 μg pDNA per mouse, i.v.), pRLN + pPD-L1 LCP (Combo, 30 μg pDNA for each plasmid per mouse, i.v.), recombinant RLN (30 μg/kg , i.v.), Combo + anti-mouse CD8α (α-CD8, Bioxcell, clone 53-6.72, 200 μg per mouse, i.p.), Combo + anti-mouse CD4 (α-CD4, Bioxcell, clone GK1.5, 200 μg per mouse, i.p.), and Combo + polyclonal rat IgG (Bioxcell, 200 μg per mouse, i.p.) were given at respective schedules. ..

    Recombinant:

    Article Title: Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy
    Article Snippet: .. PBS, pGFP LCP (30 μg pDNA per mouse, i.v.), pRLN LCP (30 μg pDNA per mouse, i.v.), pPD-L1 trap LCP (30 μg pDNA per mouse, i.v.), pRLN + pPD-L1 LCP (Combo, 30 μg pDNA for each plasmid per mouse, i.v.), recombinant RLN (30 μg/kg , i.v.), Combo + anti-mouse CD8α (α-CD8, Bioxcell, clone 53-6.72, 200 μg per mouse, i.p.), Combo + anti-mouse CD4 (α-CD4, Bioxcell, clone GK1.5, 200 μg per mouse, i.p.), and Combo + polyclonal rat IgG (Bioxcell, 200 μg per mouse, i.p.) were given at respective schedules. ..

    other:

    Article Title: Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
    Article Snippet: Anti-mouse PD-L1 Ab (clone 10F.9G2), α-mouse CD8 Ab (clone 53-6.7), α-mouse CD4 Ab (clone GK1.5) and α-mouse IFN-γ Ab (clone XMG1.2) were purchased from Bio X Cell (West Lebanon, NH, USA).



    Similar Products

    Image Search Results